The application process for PTC Therapeutics Inc’s ninth annual STRIVE awards program is now open. Eligible organizations, visit PTC Therapeutics to complete an application. The deadline for submissions is March 17, 2023.
Through this program, PTC awards grants to patient advocacy organizations who are committed to developing initiatives that address the needs of the Duchenne Muscular Dystrophy (Duchenne) community. Organizations may submit entries to fund 2023 projects focused on one of two categories: Innovation or Transition to Adulthood.
“For 25 years, we have remained committed to supporting the Duchenne community,” said Mary Frances Harmon, Senior Vice President, Corporate Relations, PTC Therapeutics. “We created STRIVE in 2015 to encourage and reward innovation by patient advocacy organizations by supporting their unique ideas and programs that help to address the needs of people living with Duchenne around the world. We are excited to see the 2023 submissions.”
Since its inception, STRIVE has supported 39 patient-focused initiatives from not-for-profit organizations in 20 countries. Past STRIVE grant recipients have developed programs to support the transition from adolescence to adulthood, improved access to diagnosis and treatment, supplied vital physical and social care to those affected and their caregivers, created career opportunities for adults with Duchenne and raised awareness of the disease in educational, public, and healthcare settings.
Recipients of the 2023 STRIVE Awards will be announced in September.
About the STRIVE Awards Program
PTC launched the Strategies to Realize Innovation, Vision, and Empowerment (STRIVE) Awards program in 2015 to support initiatives that benefit the Duchenne community by increasing awareness, diagnosis and education and fostering the development of future patient advocates. Each year, an independent panel of external experts with knowledge in rare diseases, patient advocacy and funding initiatives judges the entries for innovation, vision, and empowerment.
[Source(s): PTC Therapeutics Inc, PR Newswire]